This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by KIANG, D. T Articles by KENNEDY, B. J Search for Related Content PubMed PubMed Citation Articles by KIANG, D. T Articles by KENNEDY, B. J

Mechanism of the Hypocalcemic Effect of Mithramycin^*

Section of Medical Oncology, Department of Medicine, and the Division of Nuclear Radiology, Department of Radiology, University of Minnesota School of Medicine Minneapolis, Minnesota 55455

Address requests for reprints to: Dr. David T. Kiang, Box 168, University Hospitals, Minneapolis, Minnesota 55455.

Mithramycin is effective in the treatment of hypercalcemia. The mechanism of its hypocalcemic effect was studied in six patients with hypercalcemia by serum ⁸⁵Sr or ⁴⁵Ca kinetic techniques. Mithramycin was given at two dosage levels (25 or 50µg/kg iv). Mithramycin at the low dosage had little effect on the rate of bone accretion. However, at both dosage levels, mithramycin caused an upward shift of the slope of the specific activity curve, indicating an inhibitory effect on bone resorption. This effect started 6-12 h after a 25-µg/kg dose of mithramycin and lasted from 4-6 days. It appears that mithramycin has a preferential effect on bone resorption. (J Clin Endocrinol Metab 48: 341, 1979)

^* This work was supported by National Cancer Institute Grants CB-64000 and CA-19527, The Minnesota Medical Foundation, and the Masonic Memorial Hospital Fund, Inc.

Received May 25, 1978.

This article has been cited by other articles:

				S.-C. J. Yeung, A. C. Chiu, R. Vassilopoulou-Sellin, and R. F. Gagel The Endocrine Effects of Nonhormonal Antineoplastic Therapy Endocr. Rev., April 1, 1998; 19(2): 144 - 172. [Abstract] [Full Text]

				F. R. Singer, P. S. Ritch, T. E. Lad, Q. S. Ringenberg, J. H. Schiller, R. R. Recker, and E. Ryzen Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate: A Controlled, Multicenter Study Arch Intern Med, March 1, 1991; 151(3): 471 - 476. [Abstract] [PDF]

				T. E. Lad, H. M. Mishoulam, D. H. Shevrin, L. J. Kukla, E. C. Abramson, and S. C. Kukreja Treatment of Cancer-Associated Hypercalcemia With Cisplatin Arch Intern Med, February 1, 1987; 147(2): 329 - 332. [Abstract] [PDF]

				J. M. Meythaler, A. B. Korkor, T. Nanda, N. A. Kumar, and M. Fallon Immobilization Hypercalcemia Associated With Landry-Guillain-Barre Syndrome: Successful Therapy With Combined Calcitonin and Etidronate Arch Intern Med, August 1, 1986; 146(8): 1567 - 1571. [Abstract] [PDF]

				D. Juan Hypocalcemia: Differential Diagnosis and Mechanisms Arch Intern Med, October 1, 1979; 139(10): 1166 - 1171. [Abstract] [PDF]